How the anti-Gal antibody saved our ancestral primates from extinction
Lefevre Hall Room 106
About the Speaker
Dr. Uri Galili received his Ph.D. from the Department of Cancer Research at the Hebrew University in Jerusalem, and after a post-doctoral fellowship at the Karolinska Institute in Stockholm, he returned to the Department of Hematology in the Hadassah Hospital of the Hebrew University. It was there in 1984 that he and his colleagues published the first articles describing anti-Gal antibody and alpha-gal, the blood group carbohydrate that anti-Gal recognizes. In almost all mammals, alpha-gal is abundant and anti-Gal is absent. But in catarrhine primates—old-world monkeys, apes, and humans—the reverse is true: alpha-gal is absent and anti-Gal is the most abundant antibody in circulation. That discovery has been the linchpin of an extraordinary career that has reached into foundations of medicine, immunology, transplantation biology, and physical anthropology.
For 38 years, at the University of California San Francisco (1984–1991), the Hahnemann School of Medicine (1991–1999), Rush University School of Medicine (1999– 2004), the University of Massachusetts Medical School (2004–2013), and now in retirement back at Rush as volunteer adjunct professor, Galili has collaborated with colleagues from across the landscape of biomedical research, publishing over 100 articles exploring the anti-Gal antibody’s manifold implications, including especially the innovative therapeutic opportunities it has brought to light.
For additional information about Dr. Galili and his visit to MU, see this webpage.
Dr. Uri Galili, Ph.D.
Division of Cardiology
Rush University Medical Center